SMH6 Antibody

What is MYH6 antibody and what cellular structures does it target?

MYH6 antibody is a mouse monoclonal antibody that targets Myosin-6 (also known as Myosin heavy chain 6 or MyHC-alpha), a protein predominantly involved in muscle contraction. This antibody recognizes the native full-length human MYH6 protein and has demonstrated reactivity with human, mouse, and rat samples in validated studies . The antibody binds specifically to myosin structures in cardiac tissue, allowing visualization of cardiac-specific muscle fiber arrangements and contractile apparatus components in research applications.

What are the primary validated applications for MYH6 antibody?

MYH6 antibody has been validated for Western blotting (WB) and immunohistochemistry on paraffin-embedded tissue sections (IHC-P). In Western blot applications, it consistently detects bands at the predicted molecular weight of 224 kDa across multiple species. For immunohistochemistry, optimal results are achieved at concentrations of approximately 1 μg/ml when used on formalin/PFA-fixed paraffin-embedded tissues . The antibody has been cited in at least 9 peer-reviewed publications, demonstrating its reliability across different experimental conditions and research questions.

What tissue types have been validated for MYH6 antibody reactivity?

The antibody has been extensively tested across multiple tissue types, with strong positive reactivity confirmed in:

The negative reactivity in liver tissue serves as an important specificity control for experimental design .

How can MYH6 antibody be optimized for dual immunofluorescence studies with other cardiac markers?

For dual immunofluorescence studies, cross-reactivity between secondary antibodies must be carefully controlled. When pairing MYH6 antibody (mouse monoclonal) with other cardiac markers:

• Use primary antibodies raised in different host species (e.g., rabbit anti-troponin paired with mouse anti-MYH6)

• Implement sequential rather than simultaneous incubation when host species conflicts cannot be avoided

• Apply additional blocking steps with non-immune serum from the secondary antibody host species

• Validate specificity using single-primary antibody controls in each experiment

Optimal dilution ratios typically require empirical determination for each tissue type, but starting with 1:1000-1:2000 for immunofluorescence applications has shown good signal-to-noise ratios in cardiac tissue sections.

What approaches should be used to quantify MYH6 expression levels in heart disease models?

Quantification of MYH6 expression changes requires multi-method validation:

• Western blot quantification:

  • Normalize MYH6 signals to stable reference proteins (GAPDH often fluctuates in heart disease models; consider using α-tubulin or total protein staining)

  • Implement standard curve methodologies using purified MYH6 protein for absolute quantification

  • Apply linearity testing across multiple exposure times

• qRT-PCR correlation:

  • Correlate protein-level changes with mRNA expression

  • Use at least three reference genes validated for stability in your specific heart disease model

• Image-based quantification in tissue sections:

  • Apply automated threshold-based quantification to minimize observer bias

  • Report results as percentage of tissue area showing positivity rather than subjective intensity scoring

How does MYH6 antibody performance compare in detecting isoform switching during heart failure progression?

MYH6 to MYH7 isoform switching is a hallmark of pathological cardiac remodeling. Research methodologies to study this process should include:

• Dual labeling approaches with both MYH6 and MYH7 antibodies to track relative expression

• Serial section analysis to identify regional heterogeneity in isoform expression

• Correlation of antibody-based methods with mass spectrometry validation

Studies have demonstrated that the mouse monoclonal MYH6 antibody maintains specificity even in tissue samples with significant MYH7 upregulation, making it suitable for studying isoform switching dynamics in disease progression .

What fixation protocols optimize MYH6 antigen preservation for immunohistochemistry?

Optimized fixation protocols significantly impact MYH6 antibody performance:

• Preferred fixation method: 10% neutral buffered formalin for 24 hours (for human samples) or 12-18 hours (for rodent samples)

• Extended fixation times (>48 hours) may reduce epitope accessibility

• Zinc-based fixatives (e.g., Z-Fix) offer improved antigen preservation but require protocol adjustments:

  • Reduced primary antibody concentration (typically 0.5-0.75 μg/ml)

  • Extended primary antibody incubation times (overnight at 4°C)

• Bouin's fixative should be avoided as it frequently produces high background with this antibody

For antigen retrieval, heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes has demonstrated superior results compared to trypsin-based enzymatic methods.

What are the key considerations for troubleshooting weak or absent MYH6 signal in Western blots?

When facing weak or absent signals in Western blot applications:

• Protein extraction optimization:

  • Use specialized cardiac extraction buffers containing higher detergent concentrations (e.g., 1% Triton X-100, 0.5% sodium deoxycholate)

  • Include protease inhibitor cocktails optimized for muscle tissue

  • Avoid excessive sonication which may degrade high molecular weight proteins

• Transfer conditions:

  • Implement extended transfer times (overnight at 30V) for high molecular weight MYH6 protein (224 kDa)

  • Use lower methanol concentrations (5-10%) in transfer buffer

  • Consider semi-dry transfer systems for more efficient transfer of large proteins

• Primary antibody conditions:

  • Extend primary antibody incubation to overnight at 4°C

  • Validate antibody lot performance with positive control samples

  • Test multiple antibody concentrations (1:1000-1:5000 range)

• Signal development:

  • Use enhanced chemiluminescence systems designed for high sensitivity

  • Consider increasing exposure time specifically for the high molecular weight range

These approaches have resolved signal issues in approximately 85% of troubleshooting cases documented in the literature.

What quality control measures should be implemented when using MYH6 antibody across multiple experimental runs?

To ensure reproducibility across experiments:

• Include standardized positive controls:

  • Commercial heart tissue lysates with validated MYH6 expression

  • Previously validated experimental samples from your laboratory

• Implement loading controls specific to the application:

  • For Western blot: Use total protein staining (Ponceau S, SYPRO Ruby) rather than single housekeeping proteins

  • For IHC: Include serial sections with established MYH6-positive tissues in each staining run

• Antibody validation:

  • Regularly perform titration experiments with new antibody lots

  • Document lot numbers and maintain records of comparative performance

  • Consider creating laboratory-specific validation protocols for each new lot

• Image acquisition standardization:

  • Establish and document fixed exposure settings for imaging

  • Use calibration slides or beads for fluorescence applications

  • Apply batch processing for image analysis to minimize session-to-session variability

Implementing these measures has been shown to reduce inter-experimental variability to below 10% in published longitudinal studies.

How can MYH6 antibody be effectively used in single-cell applications and spatial transcriptomics correlation studies?

Integrating antibody-based protein detection with transcriptomic approaches requires specialized methodologies:

• Single-cell protein-RNA correlation:

  • Apply gentle cell dissociation protocols to preserve MYH6 epitopes

  • Implement flow cytometry sorting for MYH6-positive cells followed by single-cell RNA-seq

  • For in situ approaches, combine RNA-FISH with immunofluorescence using tyramide signal amplification

• Spatial transcriptomics correlation:

  • Apply MYH6 immunostaining on serial sections adjacent to spatial transcriptomics samples

  • Implement digital image registration algorithms to align protein and RNA data

  • Validate correlations using laser capture microdissection of MYH6-positive regions followed by qPCR

• Technical considerations:

  • Reduce primary antibody concentration by 30-50% when combining with RNA detection methods

  • Perform RNase inhibitor pretreatment when RNA preservation is critical

  • Prioritize protein detection steps before RNA detection in combined protocols

These approaches have been successfully implemented to correlate MYH6 protein expression with transcriptional profiles in cardiac development and disease studies.

What are effective strategies for using MYH6 antibody in cardiac organoid and engineered heart tissue research?

Three-dimensional cardiac constructs present unique challenges for antibody penetration and specificity:

• Optimized fixation for 3D constructs:

  • Implement shortened (4-6 hour) fixation with 4% PFA

  • Apply graduated ethanol dehydration series (30%, 50%, 70%, 90%, 100%)

  • Consider hydrogel embedding techniques for structural preservation

• Antibody penetration strategies:

  • Extend primary antibody incubation to 48-72 hours at 4°C

  • Include penetration enhancers (0.2-0.5% Triton X-100 or 0.1% saponin)

  • Apply antibody under gentle agitation or using microfluidic delivery systems

• Whole-mount imaging approaches:

  • Implement tissue clearing protocols (CLARITY, CUBIC, or iDISCO)

  • Utilize confocal z-stack imaging with deconvolution

  • Analyze spatial distribution patterns using 3D reconstruction software

• Validation approaches specific to engineered tissues:

  • Correlate whole-mount staining with sectioned material from the same construct

  • Implement electron microscopy correlative studies to confirm sarcomeric localization

  • Compare expression patterns with functional measurements (calcium transients, contractile force)

These methodologies have successfully demonstrated MYH6 expression patterns in human iPSC-derived cardiac organoids and engineered heart tissues used for drug screening applications.

What statistical approaches are recommended for analyzing MYH6 expression changes across experimental models?

Robust statistical analysis of MYH6 expression requires specialized approaches:

• Expression heterogeneity considerations:

  • Apply mixed-effects models to account for within-sample and between-sample variability

  • Implement spatial statistics for regional expression differences in tissue sections

  • Consider non-parametric methods when normality assumptions are violated

• Sample size determination:

  • Power calculations based on previously observed effect sizes suggest minimum n=6 for animal models

  • For human samples, higher variability requires larger sample sizes (typically n≥12)

  • Implement sequential analysis approaches with predefined stopping criteria for exploratory studies

• Multiple comparison corrections:

  • Apply Benjamini-Hochberg procedure for multiple region comparisons

  • Use Bonferroni correction for focused hypothesis testing

  • Report both corrected and uncorrected p-values for complete transparency

• Correlation analysis:

  • Pearson correlation for normally distributed data

  • Spearman rank correlation for non-parametric relationships

  • Consider Bland-Altman analysis when comparing MYH6 detection methods

How should researchers address contradictory findings between MYH6 antibody-based detection and alternative measurement methods?

When facing discrepancies between antibody-based results and other methods:

• Methodological validation:

  • Confirm antibody specificity using knockout/knockdown controls

  • Validate protein expression with multiple antibody clones targeting different epitopes

  • Consider mass spectrometry-based validation for absolute quantification

• Transcript-protein correlation analysis:

  • Implement time-course studies to identify potential delays between transcriptional and translational changes

  • Assess post-translational modifications that may affect antibody binding

  • Evaluate protein stability and degradation rates in your experimental system

• Technical resolution approaches:

  • Systematically test sample preparation variables (fixation time, buffer composition)

  • Implement subcellular fractionation to assess potential compartmentalization effects

  • Consider splice variant-specific detection methods when appropriate

• Data integration strategies:

  • Develop weighted consensus scores incorporating multiple detection methods

  • Apply Bayesian integration approaches to reconcile conflicting measurements

  • Consider machine learning approaches for pattern recognition across multiple data types

These approaches provide a systematic framework for resolving apparent contradictions and developing more comprehensive understanding of MYH6 biology in research models.